Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 28; pp. v611 - v612
Main Authors Ascierto, P.A., Bono, P., Bhatia, S., Melero, I., Nyakas, M.S., Svane, I-M., Larkin, J., Gomez-Roca, C., Schadendorf, D., Dummer, R., Marabelle, A., Hoeller, C., Maurer, M., Harbison, C.T., Mitra, P., Suryawanshi, S., Thudium, K., Muñoz Couselo, E.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2017
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdx440.011